Vertex Updates Incivek Label to Note Fatal Skin Reactions

Vertex Pharmaceuticals (NASDAQ: VRTX  ) updated the label on its hepatitis C drug Incivek to include a boxed warning stating that fatal and non-fatal serious skin reactions have been reported in patients taking Incivek combined with peginterferon alfa and ribavirin.

The label previously mentioned reports of serious skin reactions in the warnings and precautions section, and that the drug combination should be discontinued immediately when serious skin reactions occur, but didn't mention that it could be fatal. Less than 1% of patients in the phase 3 clinical trials were diagnosed with a serious skin reaction, and all recovered after discontinuing the drug regimen.

After deaths occurred from patients continuing to take the medication after a serious skin reaction was identified, Vertex, in combination with the Food and Drug Administration, decided to highlight the potential side effects in a boxed warning on the label.

The label was also updated to include additional information on the time to onset and management of anemia in patients taking Incivek combination.

link


Read/Post Comments (0) | Recommend This Article (0)

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

Be the first one to comment on this article.

DocumentId: 2164279, ~/Articles/ArticleHandler.aspx, 4/23/2014 5:31:55 AM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...


Advertisement